Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the third quarter ended September 30, 2017, on November 7, 2017, after the NASDAQ market closing.
The company will not conduct a conference call in conjunction with this financial results press release.
About CytomX Therapeutics